Bromazepam is an intermediate-acting benzodiazepine developed by Roche in the 1970s and marketed primarily in Europe and South America under trade names including Lexotan, Lexotanil, and Lexomil. It is prescribed for the short-term treatment of anxiety, panic disorder, and tension states. As a classical benzodiazepine, bromazepam produces sedation, anxiolysis, muscle relaxation, and anticonvulsant effects through positive allosteric modulation of GABA-A receptors throughout the central nervous system.
Bromazepam is pharmacologically unremarkable relative to other members of its class — it produces typical benzodiazepine effects at therapeutic doses, with a duration of action of approximately 6–8 hours and a half-life of 10–20 hours. It is less commonly encountered in recreational contexts than diazepam, clonazepam, or alprazolam, but carries the same risks of tolerance, dependence, and withdrawal that characterize the entire benzodiazepine class. Experience reports describe a clean anxiolytic effect suitable for acute anxiety, without the pronounced sedation of some longer-acting benzodiazepines.
Despite its moderate profile, bromazepam is subject to significant misuse in some regions, particularly Spain, France, and parts of Latin America, where it has historically been more permissively prescribed than in the United States or United Kingdom. Its structural novelty — incorporating a pyridine ring rather than a phenyl group at the 5-position — does not confer any meaningful pharmacological distinction from other classical benzodiazepines.